Penumbra, Inc. (PEN)
Health Care · medical devices · NYSE
Penumbra is a medical device innovator specializing in mechanical thrombectomy and embolization technologies to treat neurovascular and peripheral vascular conditions.
What Penumbra, Inc. does
Penumbra, Inc. is a global healthcare company that develops, manufactures, and markets innovative medical devices for neurovascular and peripheral vascular conditions. The company's product portfolio focuses on minimally invasive mechanical thrombectomy and embolization technologies used by physicians to treat stroke and other vascular diseases.
Themes: neurovascular intervention, mechanical thrombectomy, minimally invasive surgery, vascular health
Fundamentals
- Price$317.52 as of 2026-10-08 close
- Market cap$12.5B as of 2026-07-14 (share count; price 2026-10-08)
- 1-year return+22.6% 2025-10-08 close $258.95 → 2026-10-08 close $317.52
- P/E77.99 as of 2026-10-08
- Net margin+12.7% FY2025, SEC XBRL
- Gross margin+67.1% FY2025, SEC XBRL
- ROE+12.4% FY2025, SEC XBRL
- Debt / equity0.01 as of 2026-09-02
- Revenue growth (YoY)+17.6% as of 2026-09-02
- Revenue CAGR (3y)+18.3% SEC XBRL
- Beta0.54 as of 2026-09-02
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
How PEN compares in its sector
- price-to-earnings ratiotop 25% 185 covered Health Care peers, as of 2026-10-08
- net profit margintop 25% 430 covered Health Care peers, as of 2026-09-02
- operating margintop 25% 417 covered Health Care peers, as of 2026-09-02
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-02
- return on equitytop 25% 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
PEN is not currently in any published Top 10 list. Its scores are below.
Top 10 score
52.3 #607 of 1,379 scored · #72 of 151 in Health Care
Growth 77th (3-year revenue CAGR 18.3%, revenue growth year over year 17.6%) and financial health 71st (debt to equity 0, free cash flow margin 12.5%); weakest is valuation (17th, price to earnings 78, price to book 8.2).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
How Penumbra, Inc. looks technically
Penumbra, Inc. (PEN) is trading 2.9% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 35 trading days ago — a "death cross", a bearish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 5 trading days ago (its momentum flipped negative). It made a new 20-day low about 2 trading days ago. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 2% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 2.9% below its 200-day average, the long-term trend line — a long-term downtrend | -2.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $321.41 | $321.41 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $326.88 | $326.88 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 100 calendar days ago — the swings before that are what the structure reading is measured on | 100 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 314.8. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 35 trading days ago — a "death cross", a bearish long-term signal | 35 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend) | 23.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30) | 42.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($316.32 to $320.27) — its "stochastic" reading is 30 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 30.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 5 trading days ago (its momentum flipped negative) | 5 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $362.41 | $362.41 |
|---|---|---|
| From the 52-week high | it is 12.4% below its 52-week high (its highest price of the past year) | -12.4% |
| Above the 52-week low | it is 43.5% above its 52-week low (its lowest price of the past year) | +43.5% |
| Below the 52-week high | it is 12.4% below its highest point of the past year | 12.4% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day low about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $362.41 (set on 2026-01-21) | $362.41 |
| Given back of the 52-week move | over the past year its closes ranged ($225.54 to $359.40), and it has given back roughly a third of its rise from last year’s low — 31% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $272.39 to $276.67. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 31.3% |
| From the all-time high | it is 12.4% below its all-time high | -12.4% |
| Nearest price level | it is sitting right on a resistance level at $318.29 — a price it turned at 12 times since 2025-12-22, most recently on 2026-09-24. Since 2024-10-08 it has 10 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.2% |
| All-time low | its lowest closing price on record is $35.31 (set on 2015-10-22) | $35.31 |
| Above the all-time low | it is 799.1% above its all-time low | +799.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 2% of the past ~6 months), which often precedes a bigger move | 2nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.57 between its high and its low — about 0.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.57 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $316.47 and $320.24 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $316.47 – $318.35 – $320.24 |
| Typical daily range (% of price) | its price moves about 0.5% in a typical session — among the calmest in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 0.5% |
| Stretch from the 200-day average | it is trading 6.0 daily ranges below its 200-day average price (2.9% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale. Read that multiple with care: this company's daily range is unusually small (about 0.5% of its price), which is what makes the multiple large — a stock trading in a narrow band near a takeover price does this | 6.0 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.03× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | 2 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 2 sessions ago |
|---|---|---|
| Since a hammer | 7 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 7 sessions ago |
Price gaps
1
| Gap at the open | it opened on 2026-10-08 at essentially the same price it closed at the session before — no meaningful overnight gap | +0.1% |
|---|
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 1.6 percentage points (the stock lost 0.5% while the market gained 1.0%) | -1.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 3.8 percentage points (the stock gained 0.1% while the market gained 3.8%) | -3.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 21.2 percentage points (the stock lost 3.7% while the market gained 17.5%) | -21.2% |
| vs market, 12 months | over the past 12 months this stock beat the market by 7.6 percentage points (the stock gained 22.6% while the market gained 15.0%) | +7.6% |
Signal agreement
2
| Bullish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bullish state — these describe past price behaviour, not a forecast | 0 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 1.2% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 0.6% of the share price, which is taken to mean a barrier that gives way easily. | -1.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 5% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $333.94 — a volume-weighted average of daily closes over 191 sessions, not a true tick-by-tick VWAP. | -4.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% below the average price paid since it last reported on 2026-07-30 (its 10-Q), so the typical buyer over that stretch is under water. That average is $320.79 — a volume-weighted average of daily closes over 50 sessions, not a true tick-by-tick VWAP. | -1.0% |
Price levels it has turned at before
PEN last closed at $317.52 on 2026-10-08. Since 2024-10-08 it has turned at 10 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $318.29 | Resistance | 0.2% above the last close | turned there 12 times · 2025-12-22 to 2026-09-24 |
| $309.50 | Support | 2.5% below the last close | turned there twice · 2025-02-19 to 2025-05-09 |
| $326.40 | Resistance | 2.8% above the last close | turned there five times · 2026-03-30 to 2026-09-02 |
| $303.05 | Support | 4.6% below the last close | turned there three times · 2025-04-25 to 2026-01-02 |
| $336.86 | Resistance | 6.1% above the last close | turned there five times · 2026-02-11 to 2026-04-23 |
| $287.57 | Support | 9.4% below the last close | turned there five times · 2025-03-25 to 2026-01-13 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $314.80.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $387.21 and $431.96 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $314.80.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Broke down to a new 20-day low · MACD just crossed bearish (12/26/9) · in a Bollinger Band volatility squeeze · lagging the market · Least volatile (2% or less typical daily range) | Learn: moving average · golden cross · adx · rsi · macd · breakout · bollinger bands
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.69 mean, 1=Strong Buy…5=Strong Sell) — 12 analysts
- Mean price target$361.83 range $323.00 – $374.00; median $374.00
Analyst estimates, as of 2026-10-04. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for PEN
- Consensus EPS estimate$1.18 next reporting period, as of 2026-10-04
- Estimate change, 30 days$0.00 (0.0%) from $1.18, on 2026-08-30, 35-day window
- Readings revised upward0% of 5 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on a limited number of high-growth product platforms.","Significant competition from larger, well-funded medical device manufacturers.","Risks associated with international operations and foreign currency exchange fluctuations."]
What changed in the latest 10-Q
AI-assisted comparison of PEN's 10-Q filed 2026-05-06 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to merger agreement with Boston Scientific Corporation entered January 14, 2026, at enterprise value of approximately $14.5 billion with $374 per share valuation (73% cash, 27% stock) and expected closing by end of 2026
- Addition of 'Flash' to peripheral thrombectomy INDIGO System product list
- Addition of 'Ruby LP' and 'Ruby XL' to peripheral embolization product descriptions
- Addition of 'SwiftSET' to neuro embolization products
- Addition of 'Access25' to access product delivery catheters
- Three months ended March 31, 2026 revenue of $374.8 million and 2025 revenue of $324.1 million with $50.6 million increase
- Three months ended March 31, 2026 operating income of $38.2 million and 2025 operating income of $40.4 million
- Foreign exchange revenue percentage of 20.9% for three months ended March 31, 2026 and 20.8% for 2025
- Reference to Form 10-K for year ended December 31, 2025 filed February 25, 2026
- Removed:
- Reference to impairment charge of $110.3 million related to immersive healthcare asset group during nine months ended September 30, 2024
- Statement regarding permanent cessation of immersive healthcare product sales in three months ended September 30, 2024
- Restructuring costs disclosure regarding immersive healthcare wind down for three and nine months ended September 30, 2025
- 'Flash' is now listed in newer filing; 'Lightning' appears in older but only 'Lightning' in product list context of older filing - correction: Lightning remains in newer
- 'RUBY Embolization Platform' changed to 'Ruby, Ruby LP and Ruby XL Embolization Platforms'
- 'PAC400' standalone changed to include 'SwiftSET' in neuro embolization
- Three months ended September 30, 2025 revenue of $354.7 million and 2024 revenue of $301.0 million
- Three months ended September 30, 2025 operating income of $48.8 million and 2024 operating income of $35.4 million
- Nine months revenue and operating income comparisons for September 30 periods
- Foreign exchange revenue percentages for September 30, 2025 and 2024 (22.5%, 24.8%, and nine-month data 22.2%, 25.6%)
- Reference to Form 10-K for year ended December 31, 2024 filed February 18, 2025
- Reworded:
- INDIGO System description changed from 'Lightning, Bolt' to 'Lightning, Flash, Bolt' in peripheral thrombectomy
- 'RUBY Embolization Platform' changed to 'Ruby, Ruby LP and Ruby XL Embolization Platforms' in peripheral embolization
- Access product delivery catheters expanded from 'Neuron, Neuron MAX, BENCHMARK, BMX, DDC, PX SLIM, and MIDWAY' to include 'Access25'
- Neuro embolization products changed from 'Penumbra SMART COIL, Penumbra Coil 400, POD400, PAC400 and SwiftPAC Coil' to include 'SwiftSET'
- Notes:
- Older filing covers nine months ended September 30, 2025; newer filing covers three months ended March 31, 2026 - different reporting periods make some comparisons not directly comparable
- Text appears truncated at end of both filings in provided excerpts, so 'Factors Affecting Our Performance' section may have additional changes not visible
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
Most recent open-market transaction: 2026-04-02. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about PEN's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 1 matched disclosure for PEN from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding PEN as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 6,836,221
- Reported value $2,158,534,477
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about PEN's institutional holders → See what each manager we track holds →
Short interest (FINRA)
PEN had 1,805,942 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
PEN had 4.58% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.18 days to cover at the same settlement.
- Reported short interest (shares) 1,805,942
- Short interest (% of shares outstanding) 4.58%
- Prior settlement (shares) 1,731,493
- Reported change 4.3%
- Days to cover (reported) 7.18
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare PEN vs…
Penumbra, Inc. is found in…
Frequently asked questions
What does Penumbra, Inc. (PEN) do?
Penumbra, Inc. is a global healthcare company that develops, manufactures, and markets innovative medical devices for neurovascular and peripheral vascular conditions. The company's product portfolio focuses on minimally invasive mechanical thrombectomy and embolization technologies used by physicians to treat stroke and other vascular diseases.
What sector is Penumbra, Inc. (PEN) in?
Penumbra, Inc. (PEN) is classified in the Health Care sector. Its industry is medical devices. It trades on NYSE.
Who are Penumbra, Inc.'s (PEN) competitors?
Notable peers of Penumbra, Inc. (PEN) include Stryker, Medtronic, Boston Scientific and Johnson & Johnson / Cerenovus. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in PEN?
Yes — we hold 1 matched STOCK Act disclosure for PEN from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Penumbra, Inc. (PEN) overbought or oversold right now?
Penumbra, Inc. (PEN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 42, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on PEN come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.